Match!
Boback Ziaeian
University of California, Los Angeles
CardiologyIntensive care medicineHeart failureDiabetes mellitusMedicine
65Publications
16H-index
990Citations
What is this?
Publications 75
Newest
#1Boback Ziaeian (UCLA: University of California, Los Angeles)H-Index: 16
#2Haolin Xu (Durham University)H-Index: 8
Last. Eric E. Smith (U of C: University of Calgary)H-Index: 72
view all 8 authors...
Background: The U.S. lacks an appropriate stroke surveillance system. This study developed and validated post-stratification weights for an existing stroke patient registry to represent the entire ...
Source
#1Nikhil Bassi (UCLA: University of California, Los Angeles)H-Index: 4
#2Boback Ziaeian (UCLA: University of California, Los Angeles)H-Index: 16
Last. Gregg C. Fonarow (UCLA: University of California, Los Angeles)H-Index: 134
view all 4 authors...
Importance Sodium-glucose cotransporter 2 inhibitor (SGLT2-i) therapy provided incremental survival benefit to patients with heart failure and reduced ejection fraction (HFrEF) who received guideline-directed medical therapy regardless of type 2 diabetes status in a recent clinical trial. To date, estimation of the potential benefits that could be gained from optimal implementation of SGLT2-i therapy at the population level has not been quantified. Objective To quantify the projected gains for d...
Source
#1Boback Ziaeian (UCLA: University of California, Los Angeles)H-Index: 16
#2Javed Butler (UMMC: University of Mississippi Medical Center)H-Index: 37
Last. Gregg C. FonarowH-Index: 134
view all 3 authors...
Source
Source
#1Abhishek Chaturvedi (Allegheny General Hospital)
Last. Raymond L. BenzaH-Index: 34
view all 9 authors...
Heart failure is a significant cause of morbidity and mortality in cancer patients (CP). While they are often not candidates for transplantation, alternate advanced therapies, such as LVAD, may provide hope for life prolongation. We examined national trends in the use of LVAD and associated outcomes
Source
#1Pratyaksh K. Srivastava (UCLA: University of California, Los Angeles)H-Index: 2
#2Jeffrey J. Hsu (UCLA: University of California, Los Angeles)H-Index: 9
Last. Gregg C. Fonarow (UCLA: University of California, Los Angeles)H-Index: 134
view all 4 authors...
To describe the epidemiology, pathophysiology, management, and prognosis of patients with heart failure with mid-range ejection fraction (HFmrEF). In 2013, The American Heart Association (AHA)/American College of Cardiology (ACC) assigned an ejection fraction (EF) range to heart failure with reduced ejection fraction (HFrEF, EF ≤ 40%) and heart failure with preserved ejection fraction (HFpEF, EF ≥50%). This classification created a “gray zone” of patients with EFs between 41% and 49% that ultima...
Source
Gregg C. Fonarow, MD, FACC, FAHA, Chair [∗][1] Biykem Bozkurt, MD, PhD, FACC[∗][1] Sandeep Das, MD, MPH[∗][1] Michael E. Hall, MD, MS, FAHA, FACC[∗][1] Hani Jneid, MD, FACC, FAHA[∗][1] Corrine Y. Jurgens, PhD, RN, ANP-BC, FAHA[∗][1],[†][2] Patricia Keegan, DNP, APRN, NP-C[‡][3
Source
#1Pratyaksh K. Srivastava (UCLA: University of California, Los Angeles)H-Index: 2
#2Gregg C. Fonarow (UCLA: University of California, Los Angeles)H-Index: 134
Last. Boback Ziaeian (UCLA: University of California, Los Angeles)H-Index: 16
view all 4 authors...
Background Patient characteristics insufficiently explain disparities in cardiovascular outcomes among hospitalized patients, suggesting a role for community or hospital‐level factors. Here, we eva...
Source
Source
#1Donna K. ArnettH-Index: 85
#2Roger S. BlumenthalH-Index: 80
Last. J. William McEvoyH-Index: 2
view all 18 authors...
Author(s): Arnett, Donna K; Blumenthal, Roger S; Albert, Michelle A; Buroker, Andrew B; Goldberger, Zachary D; Hahn, Ellen J; Himmelfarb, Cheryl Dennison; Khera, Amit; Lloyd-Jones, Donald; McEvoy, J William; Michos, Erin D; Miedema, Michael D; Munoz, Daniel; Jr, Smith Sidney C; Virani, Salim S; Sr, Williams Kim A; Yeboah, Joseph; Ziaeian, Boback
1 CitationsSource
12345678